{"denoms":[{"counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"45"},{"groupId":"BG005","value":"13"},{"groupId":"BG006","value":"81"}],"units":"Participants"}],"groups":[{"description":"Patients were treated with 15 mg melflufen as IV infusion on Day 1 and 40 mg dexamethasone oral tablet or IV infusion on Days 1, 8 and 15 of each 21-day treatment cycle. Patients could continue receiving treatment for up to 8 cycles or until they experienced unacceptable toxicity, disease progression, withdrew consent, and/or the study drug was discontinued at the discretion of the Investigator.","id":"BG000","title":"Phase I: Melflufen 15 mg + Dexamethasone"},{"description":"Patients were treated with 25 mg melflufen as IV infusion on Day 1 and 40 mg dexamethasone oral tablet or IV infusion on Days 1, 8 and 15 of each 21-day treatment cycle. Patients could continue receiving treatment for up to 8 cycles or until they experienced unacceptable toxicity, disease progression, withdrew consent, and/or the study drug was discontinued at the discretion of the Investigator.","id":"BG001","title":"Phase I: Melflufen 25 mg + Dexamethasone"},{"description":"Patients were treated with 40 mg melflufen as IV infusion on Day 1 and 40 mg dexamethasone oral tablet or IV infusion on Days 1, 8 and 15 of each 21-day treatment cycle. Patients could continue receiving treatment for up to 8 cycles or until they experienced unacceptable toxicity, disease progression, withdrew consent, and/or the study drug was discontinued at the discretion of the Investigator.","id":"BG002","title":"Phase I: Melflufen 40 mg + Dexamethasone"},{"description":"Patients were treated with 55 mg melflufen as IV infusion on Day 1 and 40 mg dexamethasone oral tablet or IV infusion on Days 1, 8 and 15 of each 21-day treatment cycle. Patients could continue receiving treatment for up to 8 cycles or until they experienced unacceptable toxicity, disease progression, withdrew consent, and/or the study drug was discontinued at the discretion of the Investigator.","id":"BG003","title":"Phase I: Melflufen 55 mg + Dexamethasone"},{"description":"Patients were treated with 40 mg melflufen as IV infusion on Day 1 and 40 mg dexamethasone oral tablet or IV infusion on Days 1, 8 and 15 of each 21-day or 28-day treatment cycle. Patients could continue receiving treatment for up to 8 cycles or until they experienced unacceptable toxicity, disease progression, withdrew consent, and/or the study drug was discontinued at the discretion of the Investigator. In Protocol amendment 4, the cycle of melflufen was increased from 21 to 28 days. For any patients on the 28-day treatment schedule, an additional dose of 40 mg dexamethasone was administered on Day 22 of each cycle.","id":"BG004","title":"Phase I + II: Melflufen 40 mg + Dexamethasone"},{"description":"Patients were treated with 40 mg melflufen as IV infusion on Day 1 of each 28-day treatment cycle. Dexamethasone was not administered as an antitumor compound. However, all patients were treated with 8 mg dexamethasone as an antiemetic on Days 1 and 2, and an optional 4 mg dexamethasone as an antiemetic on Days 3 and 4 of the same 28-day cycle, unless the Investigator decided to switch a patient to a combination regimen. Patients could continue receiving treatment for up to 8 cycles or until they experienced unacceptable toxicity, disease progression, withdrew consent, and/or the study drug was discontinued at the discretion of the Investigator.","id":"BG005","title":"Phase II: Melflufen 40 mg (Single Agent)"},{"description":"Total of all reporting groups","id":"BG006","title":"Total"}],"measures":[{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG006","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG006","value":"9"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"},{"groupId":"BG006","value":"14"}],"title":">=65 years"}],"denoms":[{"counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"23"}],"units":"Participants"}],"title":"Phase I"},{"categories":[{"measurements":[{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG004","value":"20"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"28"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG004","value":"25"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"30"}],"title":">=65 years"}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"45"},{"groupId":"BG005","value":"13"},{"groupId":"BG006","value":"58"}],"units":"Participants"}],"title":"Phase II"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"6 patients from the Phase I: Melflufen 40 mg + Dexamethasone arm were transferred to Phase I + II: Melflufen 40 mg + Dexamethasone arm. All arms for the baseline analysis were not mutually exclusive (mutually exclusive patients = 75).","title":"Age, Categorical","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"},{"groupId":"BG006","value":"11"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"3"},{"groupId":"BG006","value":"12"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"23"}],"units":"Participants"}],"title":"Phase I"},{"categories":[{"measurements":[{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"20"}],"title":"Female"},{"measurements":[{"groupId":"BG004","value":"30"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"38"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"45"},{"groupId":"BG005","value":"13"},{"groupId":"BG006","value":"58"}],"units":"Participants"}],"title":"Phase II"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"6 patients from the Phase I: Melflufen 40 mg + Dexamethasone arm were transferred to Phase I + II: Melflufen 40 mg + Dexamethasone arm. All arms for the baseline analysis were not mutually exclusive (mutually exclusive patients = 75).","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG006","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG006","value":"21"}],"title":"Caucasian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG006","value":"0"}],"title":"Not collected as per local laws"}],"denoms":[{"counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"23"}],"units":"Participants"}],"title":"Phase I"},{"categories":[{"measurements":[{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"6"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG004","value":"41"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"51"}],"title":"Caucasian"},{"measurements":[{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}],"title":"Not collected as per local laws"}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"45"},{"groupId":"BG005","value":"13"},{"groupId":"BG006","value":"58"}],"units":"Participants"}],"title":"Phase II"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"6 patients from the Phase I: Melflufen 40 mg + Dexamethasone arm were transferred to Phase I + II: Melflufen 40 mg + Dexamethasone arm. All arms for the baseline analysis were not mutually exclusive (mutually exclusive patients = 75).","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG006","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"5"},{"groupId":"BG006","value":"20"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG006","value":"2"}],"title":"Not collected as per local laws"}],"denoms":[{"counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"23"}],"units":"Participants"}],"title":"Phase I"},{"categories":[{"measurements":[{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG004","value":"37"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"49"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"8"}],"title":"Not collected as per local laws"}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"45"},{"groupId":"BG005","value":"13"},{"groupId":"BG006","value":"58"}],"units":"Participants"}],"title":"Phase II"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"6 patients from the Phase I: Melflufen 40 mg + Dexamethasone arm were transferred to Phase I + II: Melflufen 40 mg + Dexamethasone arm. All arms for the baseline analysis were not mutually exclusive (mutually exclusive patients = 75).","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The Safety Analysis Set included all patients who received at least 1 dose, or part thereof, of study drug."}